mondoBIOTECH holding AG (SIX:RARE) (“mondoBIOTECH”) today announces that, for clarification and formal purposes and with a view to the upcoming Annual Shareholders Meeting 2013 ("AGM"), the Board of Directors specifies and amends its proposal to agenda item 2 according to the Annual Report 2012 already published.
May 23, 2013mondoBIOTECH holding AG (SIX:RARE) (“mondoBIOTECH”) today announces that the Annual Shareholders Meeting 2013 will be held on 20 June 2013 at 11.00 a.m. (CET) at mondoBIOTECH's headquarters at Mürgstrasse 18 in 6370 Stans, Switzerland.
May 14, 2013mondoBIOTECH holding AG (“mondoBIOTECH”) today announces that the transaction between Pierrel S.p.A. and its shareholder Fin Posillipo S.p.A. regarding the participation of the latter directly into the share capital of Pierrel Research International AG ("PRINT"), announced by Pierrel S.p.A. on the 13 May 2013, will not have any impact on the business combination with PRINT which was announced by mondoBIOTECH on the 24 January 2013 (the "Transaction").
April 30, 2013mondoBIOTECH holding AG (SIX: RARE) (the “Company”) published today its financial results for the year 2012 and announces the satisfactory completion of the due diligence performed in relation to the business combination with the contract research organization (CRO) division of Pierrel SpA; this allows the two companies to take the necessary steps to bring the transaction to conclusion.
January 25, 2013mondoBIOTECH holding AG (“mondoBIOTECH”), a Swiss–based drug discovery company focused on repurposing drugs in rare and neglected diseases and listed on the SIX Swiss Exchange (SIX: RARE), today announces that BioPharma Invest AG (BPI) has exercised its right to convert the CHF 2.5 million loan facility granted to the Company on 11th November 2011 into common shares of the Company.
January 25, 2013Pierrel SpA (“Pierrel SpA”), a global pharmaceutical provider listed on the Italian Stock Exchange (Milan Stock Exchange: PRL), and mondoBIOTECH holding AG (“mondoBIOTECH”), a Swiss–based drug discovery company focused on repurposing drugs in rare and neglected diseases and listed on the SIX Swiss Exchange (SIX: RARE), announced today that they entered into a binding agreement for the combination of the Contract Research Organization (CRO) of Pierrel SpA with mondoBIOTECH.
December 31, 2012mondoBIOTECH holding AG (SIX: RARE) announces today that in 2013 Paolo Barbieri, CFO, will leave the Company to pursue new challenges in the Asset Management arena. After the hand-over period, Ruggero Gramatica, CEO, will take over the CFO responsibilities ad interim.
August 29, 2012mondoBIOTECH holding AG (SIX: RARE) announces today its Half Year Interim Results 2012
August 21, 2012mondoBIOTECH holding AG (SIX: RARE) announces today to have been granted the patent for the use of its medicinal product candidate DasKloster 0210 for the manufacture of a pharmaceutical composition for treatment and/or prophylaxis of Chronic Beryllium Disease by the European Patent Office.
August 16, 2012mondoBIOTECH holding AG (SIX: RARE) announces today to have been transferred from the US FDA the Orphan Drug Designation for the treatment of Idiopathic Pulmonary Fibrosis to its medicinal product candidate, DasKloster 1001.
Downloads
Contact Us:
Investor RelationsMondobiotech Holding AG
Das Kloster
Mürgstrasse 18
CH-6370 Stans
Switzerland
T +41 840 200 010
F +41 840 200 011
investor@mondobiotech.com
- Mondobiotech
- Fast fact
- Overview
- Milestones
- Board of Directors
- Management
- Location
- Products
- Product Overview
- Types of products
- Pipeline
- Rare Diseases
- About Rare Diseases
- Patient and Families
- Rare Diseases List
- Media Archive
- Investor
- Financial Information
- Key Information
- Corporate Governance
- Appointments
- Partnership
- Pipeline
- Science
- Pipeline
- Product Overview
- Research Vision